Allarity Therapeutics, Inc. has announced a series of significant corporate developments in recent filings with the SEC. On September 9, 2024, the company amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the potential sale of Placement Shares to $50 million. Additionally, on September 12, 2024, Allarity Therapeutics reported the resignation of Joan Y. Brown as Chief Financial Officer, effective immediately. Her departure was not due to any disagreements with the company's practices or policies. On the same day, the company's Board of Directors appointed Alexander Epshinsky as the new CFO. Epshinsky, a seasoned finance professional with experience in the pharmaceutical and biotech sectors, has entered into an Employment Agreement with Allarity Therapeutics, which includes a $340,000 annual base salary, potential performance-based increases, equity in the form of restricted stock units, and eligibility for annual bonuses, among other benefits. The company has also indicated a renewed focus on financing strategies to support its operational and strategic goals following the recent changes in management.

Allarity Therapeutics, Inc. has announced a series of significant corporate developments in recent filings with the SEC. On September 9, 2024, the company amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the potential sale of Placement Shares to $50 million. Additionally, on September 12, 2024, Allarity Therapeutics reported the resignation of Joan Y. Brown as Chief Financial Officer, effective immediately. Her departure was not due to any disagreements with the company's practices or policies. On the same day, the company's Board of Directors appointed Alexander Epshinsky as the new CFO. Epshinsky, a seasoned finance professional with experience in the pharmaceutical and biotech sectors, has entered into an Employment Agreement with Allarity Therapeutics, which includes a $340,000 annual base salary, potential performance-based increases, equity in the form of restricted stock units, and eligibility for annual bonuses, among other benefits. The company has also indicated a renewed focus on financing strategies to support its operational and strategic goals following the recent changes in management.